Sunstone Therapies is enrolling for SUN004, a Phase 2 study of psilocybin therapy for women with sexual assault-related PTSD. This trauma-informed trial utilizes a Shared Decision-Making framework to prioritize survivor agency and trust. Learn about our patient-led approach, which includes preparatory sessions, specialized therapeutic support, and optional long-term group integration.
Sunstone’s newest IIT offers veterans with PTSD access to breakthrough MDMA-assisted therapy research in both group and individual formats.
Why veterans’ trauma requires new therapeutic approaches.
Researchers from Sunstone Therapies, Dana-Farber Cancer Institute, Harvard Medical School, and the University of Vermont have published new findings that deepen understanding of how psilocybin-assisted group therapy can help people with cancer and depression navigate profound existential challenges.
At Sunstone Therapies, we believe healing goes deeper than the surface. While traditional oncology focuses on physical treatments, many patients still struggle with the psychological and emotional challenges of cancer. Our mission is to address the whole patient, which is why we created the 2Dose Study. This clinical trial, led by Dr. Manish Agrawal, builds on our initial study where 80% of participants experienced a greater than 50% reduction in depressive symptoms. The 2Dose Study will explore whether psilocybin is more effective than an active placebo and if two doses are better than one. The trial is open to people with all stages of cancer, not just advanced disease.
In psychedelic therapy clinical research, setting clear expectations is paramount. Transparent communication about potential disappointments can significantly reduce anxiety and foster a more grounded, trusting, and ultimately, healing journey for participants.
Learn about the crucial role therapists play in psychedelic therapy & their impact on treatment outcomes.